SAB Biotherapeutics (SABS) Income from Non-Controlling Interests (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly Income from Non-Controlling Interests came in at $67000.0 in Q2 2024, down 5.63% YoY from $71000.0 in Q3 2023, and down 1.47% on a QoQ basis from $68000.0 in Q1 2024.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Income from Non-Controlling Interests (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Income from Non-Controlling Interests data on file, last reported at $67000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | SAB Biotherapeutics | 295.88 Mn | 295.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | -662,455.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 71,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | 78,000.00 |
| Jun 30, 2021 | 74,000.00 |
| Mar 31, 2021 | 75,000.00 |